'Pay-for-delay' generic deals illegal

Share this article:
The Obama administration's Justice Department says that so-called pay-for-delay arrangements in which an innovator drug company pays a generic drug company to delay entry into the market are generally unlawful under antitrust laws.

The department provided its analysis in a brief filed at the request of the Second Circuit Court of Appeals in a case involving Bayer's payments of $349 million to Barr Laboratories to delay entry of a generic form of its Cipro antibiotic.
The department's brief says that the “anticompetitive potential of reverse payments in the Hatch-Waxman context in exchange for the alleged infringer's agreement not to compete and to eschew any challenge to the patent is sufficiently clear that such agreements should be treated as presumptively unlawful….”

The department says that individual cases should be judged on a “rule of reason” and might not be unlawful if there is a reasonable explanation for the payment involved.

If, the brief says, the transaction involves a payment to get the generic company to drop a challenge to an innovator's patent and to stay out of the market for a period of time, that would be presumptively unlawful.
But payments to generic companies might be legal if the amount is not higher than what the patent holder would have spent to defend a patent's validity in court.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?